Anebulo Pharmaceuticals (ANEB) Stock Forecast, Price Target & Predictions

ANEB Stock Forecast

Anebulo Pharmaceuticals stock forecast is as follows: an average price target of $6.00 (represents a 310.96% upside from ANEB’s last price of $1.46) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

ANEB Price Target

The average price target for Anebulo Pharmaceuticals (ANEB) is $6.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 310.96% upside from ANEB's last price of $1.46.

ANEB Analyst Ratings

Buy

According to 1 Wall Street analysts, Anebulo Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ANEB stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Anebulo Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 18, 2023	Boobalan Pachaiyappan	H.C. Wainwright	-	-	83.49%	310.96%

Row per page

Go to

The latest Anebulo Pharmaceuticals stock forecast, released on Sep 18, 2023 by Boobalan Pachaiyappan from H.C. Wainwright, set a price target of $6.00, which represents a 83.49% increase from the stock price at the time of the forecast ($3.27), and a 310.96% increase from ANEB last price ($1.46).

Anebulo Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$1.46	$1.46	$1.46
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of Anebulo Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Anebulo Pharmaceuticals's last price of $1.46. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 01, 2024	Benchmark	Speculative Buy	Speculative Buy	Hold
Sep 18, 2023	H.C. Wainwright		Buy	Initialise

Row per page

Go to

Anebulo Pharmaceuticals's last stock rating was published by Benchmark on Oct 01, 2024. The company gave ANEB a "Speculative Buy" rating, the same as its previous rate.

Anebulo Pharmaceuticals Financial Forecast

Anebulo Pharmaceuticals Revenue Forecast

	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
Revenue	-	-	-	-	-
Avg Forecast	-	-	-	-	-
High Forecast	-	-	-	-	-
Low Forecast	-	-	-	-	-
# Analysts	-	-	-	-	-
Surprise %	-	-	-	-	-

Anebulo Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ANEB's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Anebulo Pharmaceuticals EBITDA Forecast

	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-
EBITDA	-	-	-	-	-
Avg Forecast	-	-	-	-	-
High Forecast	-	-	-	-	-
Low Forecast	-	-	-	-	-
Surprise %	-	-	-	-	-

undefined analysts predict ANEB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Anebulo Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Anebulo Pharmaceuticals Net Income Forecast

	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-
Net Income	-	-	-	-	-
Avg Forecast	$-2.07M	$-2.07M	$-2.07M	$-1.30M	$-2.84M
High Forecast	$-2.07M	$-2.07M	$-2.07M	$-1.30M	$-2.84M
Low Forecast	$-2.07M	$-2.07M	$-2.07M	$-1.30M	$-2.84M
Surprise %	-	-	-	-	-

Anebulo Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ANEB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Anebulo Pharmaceuticals SG&A Forecast

	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-
SG&A	-	-	-	-	-
Avg Forecast	-	-	-	-	-
High Forecast	-	-	-	-	-
Low Forecast	-	-	-	-	-
Surprise %	-	-	-	-	-

Anebulo Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ANEB last annual SG&A of $NaN (undefined).

Anebulo Pharmaceuticals EPS Forecast

	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-
EPS	-	-	-	-	-
Avg Forecast	$-0.08	$-0.08	$-0.08	$-0.05	$-0.11
High Forecast	$-0.08	$-0.08	$-0.08	$-0.05	$-0.11
Low Forecast	$-0.08	$-0.08	$-0.08	$-0.05	$-0.11
Surprise %	-	-	-	-	-

According to undefined Wall Street analysts, Anebulo Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ANEB previous annual EPS of $NaN (undefined).

Anebulo Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PMVP	PMV Pharmaceuticals	-	-	1018.01%	Buy
ANTX	AN2 Therapeutics	-	-	552.99%	Buy
MOLN	Molecular Partners	-	-	448.20%	Buy
AVTE	Aerovate Therapeutics	-	-	388.72%	Hold
OPT	Opthea	-	-	343.04%	Buy
ANEB	Anebulo Pharmaceuticals	-	-	310.96%	Buy
ACRV	Acrivon Therapeutics	-	-	233.28%	Buy
MLYS	Mineralys Therapeutics	-	-	140.19%	Buy
ANAB	AnaptysBio	-	-	133.50%	Buy
ADAG	Adagene	-	-	128.31%	Buy

ANEB Forecast FAQ

Is Anebulo Pharmaceuticals a good buy?

Yes, according to 1 Wall Street analysts, Anebulo Pharmaceuticals (ANEB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of ANEB's total ratings.

What is ANEB's price target?

Anebulo Pharmaceuticals (ANEB) average price target is $6 with a range of $6 to $6, implying a 310.96% from its last price of $1.46. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Anebulo Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for ANEB stock, the company can go up by 310.96% (from the last price of $1.46 to the average price target of $6), up by 310.96% based on the highest stock price target, and up by 310.96% based on the lowest stock price target.

Can Anebulo Pharmaceuticals stock reach $2?

ANEB's average twelve months analyst stock price target of $6 supports the claim that Anebulo Pharmaceuticals can reach $2 in the near future.

What are Anebulo Pharmaceuticals's analysts' financial forecasts?

Anebulo Pharmaceuticals's analysts financial forecasts for the fiscal year (Jun 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-2.84M (high $-2.84M, low $-2.84M), average SG&A $0 (high $0, low $0), and average EPS is $-0.11 (high $-0.11, low $-0.11). ANEB's analysts financial forecasts for the fiscal year (Jun 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-7.521M (high $-7.521M, low $-7.521M), average SG&A $0 (high $0, low $0), and average EPS is $-0.29 (high $-0.29, low $-0.29).